HER-2/neu and MYC gene silencing in breast cancer: therapeutic potential and advancement in nonviral nanocarrier systems

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Huang C, Li M, Chen C, Yao Q. Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Expert Opin. Ther. Tar. 12, 637–645 (2008).
  Medline CASGoogle Scholar
• 2. Oh YK, Park TG. siRNA delivery systems for cancer treatment. Adv. Drug Deliv. Rev. 61, 850–862 (2009).
  Medline CASGoogle Scholar
• 3. Maiyo F, Singh M. Selenium nanoparticles: potential in cancer gene and drug delivery. Nanomedicine 12(9), 1075–1089 (2017).
  CASGoogle Scholar
• 4. Benson JR, Jatoi I. The global breast cancer burden. Future Oncol. 8, 697–702 (2012).
  CASGoogle Scholar
• 5. World Health Organization. www.who.int/cancer/detection/breastcancer/en/index1
  Google Scholar
• 6. American Cancer Society. Breast cancer facts and figures 2017/2018 (2018). www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures-2017-2018.pdf
  Google Scholar
• 7. Napoli C, Lemieux C, Jorgensen R. Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 2, 279–289 (1990).
  Medline CASGoogle Scholar
• 8. Singh A, Trivedi P, Jain NK. Advances in siRNA delivery in cancer therapy. Artif. Cells. Nanomed. Biotech. 46(2), 274–283 (2018).
  Medline CASGoogle Scholar
• 9. Dana H, Chalbatani GM, Mahmoodzadeh H et al. Molecular mechanisms and biological functions of siRNA. Int. J. Biomed. Sci. 13(2), 48–57 (2017).
  MedlineGoogle Scholar
• 10. Zhang H, Kolb FA, Jaskiewicz L, Westhof E, Filipowicz W. Single processing centre models for human Dicer and bacterial RNase III. Cell 118, 57–68 (2004).
  Medline CASGoogle Scholar
• 11. Huynh A, Madu CO, Lu Y. siRNA: a promising new tool for future breast cancer therapy. Oncomedicine 3, 74–81 (2018).
  Google Scholar
• 12. Mansoori B, Shotorbani SS, Baradaran B. RNA interference and its role in cancer therapy. Adv. Pharm. Bull. 4(4), 313–321 (2014).
  MedlineGoogle Scholar
• 13. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat. Rev. Mol. Cell. Biol. 10, 126–139 (2009).
  Medline CASGoogle Scholar
• 14. Matranga C, Tomari Y, Shin C, Bartel DP, Zamore PD. Passenger-strand cleavage facilitates assembly of siRNA into AgO₂-containing RNAi enzyme complexes. Cell 123, 607–620 (2005).
  Medline CASGoogle Scholar
• 15. Bartlett DW, Davis ME. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res. 34, 322–333 (2006).
  Medline CASGoogle Scholar
• 16. Naab TJ, Gautam A, Ricks-Santi L et al. MYC amplification in subtypes of breast cancers in African American women. BMC Cancer 18, 274–280 (2018).
  MedlineGoogle Scholar
• 17. Lodish A, Berk A, Zipursky SL et al. Proto-oncogenes and tumour suppressor genes. In: Molecular Cell Biology (4th Edition). WH Freeman (Ed.). MacMillan, NY, USA (2000).
  Google Scholar
• 18. Haschek WM, Rousseaux CG, Wallig MA. Manifestaions of toxic cell injury: cell injury/death and chemical carcinogenisis. In: Fundamentals of Toxicologic Pathology (2nd Edition). Academic Press, MA, USA 9–42 (2010).
  Google Scholar
• 19. Igbal N, Igbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutics implications. Mol. Biol. Int. 2014, 852748 (2014). • Describes the role of HER2 in various cancers and treatment strategies that target HER2.
  MedlineGoogle Scholar
• 20. Mitri Z, Constantine T, O'Regan R. The HER2 receptor in breast cancer: pathophysiology, clinical use and new advances in therapy. Chemother. Res. Pract. 2012, 743193 (2012).
  MedlineGoogle Scholar
• 21. Harbeck N, Pegram MD, Rüschoff J, Mobus V. Targeted therapy in metastatic breast cancer: the HER2/neu oncogene. Breast Care 5(Suppl. 1), 3–7 (2010).
  MedlineGoogle Scholar
• 22. Fernández Val JF, Losada J, Arregui Murua MA, Sarría R. Cell proliferation, nuclear ploidy, and EGFR and HER2/neu tyrosine kinase oncoproteins in infiltrating ductal breast carcinoma. Cancer Genet. Cytogenet. 138, 69–72 (2002).
  MedlineGoogle Scholar
• 23. Warren CM, Landgraf R. Signalling through ERBB receptors: multiple layers of diversity and control. Cell. Signal. 18, 923–933 (2006).
  Medline CASGoogle Scholar
• 24. Engel RH, Kaklamani VG. HER2-positive breast cancer: current and future treatment strategies. Drugs 67, 1329–1341 (2007).
  Medline CASGoogle Scholar
• 25. Ngamcherdtrakul W, Morry J, Gu S et al. Cationic polymer modified mesoporous silica nanoparticles for targeted siRNA delivery to HER2⁺ breast cancer. Adv. Funct. Mater. 25(18), 2646–2659 (2015).
  Medline CASGoogle Scholar
• 26. Tan WB, Jiang S, Zhang Y. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. Biomaterials 28, 1565–1571 (2007).
  Medline CASGoogle Scholar
• 27. Wang Y, Morrison G, Gillihan R et al. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers – role of estrogen receptor and HER2 reactivation. Breast Cancer Res. 13(6), R121 (2011).
  Medline CASGoogle Scholar
• 28. Wong LL, Zhang D, Chang CF, Koay ESC. Silencing of the PP2A catalytic subunit causes HER-2/neu positive breast cancer cells to undergo apoptosis. Exp. Cell Res. 16, 3387–3396 (2010).
  Google Scholar
• 29. Tai W, Qin B, Cheng K. Inhibition of breast cancer cell growth and invasiveness by dual silencing of HER-2 and VEGF. Mol. Pharm. 7, 543–556 (2010).
  Medline CASGoogle Scholar
• 30. Klauber-DeMore N, Schulte BA, Wang GY. Targeting MYC for triple-negative breast cancer treatment. Oncoscience 5, 5–6 (2018).
  Google Scholar
• 31. Horiuchi D, Camardr R, Zhou AY et al. PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumours with elevated MYC expression. Nat. Med. 22(11), 1321–1329 (2016).
  Medline CASGoogle Scholar
• 32. Chen H, Liu H, Quig G. Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct. Tar. 3, 5 (2018).
  MedlineGoogle Scholar
• 33. Fallah Y, Brundage J, Allegakoen P, Shajahan-Haq AN. MYC-driven pathways in breast cancer sub-types. Biomolecules 7, 53 (2017). • Outlines the role of MYC in different breast cancer subtypes.
  Google Scholar
• 34. Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist 16(Suppl. 1), 61–70 (2011).
  MedlineGoogle Scholar
• 35. Lee K, Giltane JM, Balko JM et al. MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells through regulation of mitochondrial oxidative phosphorylation. Cell Metab. 26(4), 633–647 (2017).
  Medline CASGoogle Scholar
• 36. Carey JPW, Karakas C, Bui T et al. Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple-negative breast cancer. Cancer Res. 78(3), 742–757 (2017).
  MedlineGoogle Scholar
• 37. Stine ZE, Walton ZE, Altman BJ, Hsieh AL, Dang CV. MYC, metabolism and cancer. Cancer Discov. 5(10), 1024–1039 (2015).
  Medline CASGoogle Scholar
• 38. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat. Rev. Cancer 8, 976–990 (2008).
  Medline CASGoogle Scholar
• 39. Xu J, Cen Y, Olopade OI. MYC and breast cancer. Genes Cancer 1(6), 629–640 (2010). •• Describes MYC protein and biological function, MYC upregulation in the breast cancer subtypes and therapeutic strategies for breast cancer.
  Medline CASGoogle Scholar
• 40. Conacci-Sorrel M, McFerrin L, Eisenman RN. An overview of MYC and its interactome. CSH Perspect. Med. 4, a014357 (2014).
  Google Scholar
• 41. Tian T, Xiaoyi L, Zhang J. mTOR signalling in cancer and mTOR inhibitor in solid tumour targeting therapy. Int. J. Mol. Sci. 20, 755 (2019).
  CASGoogle Scholar
• 42. Muthulagu N, Junttila MR, Wiese KE et al. BIM is the primary mediator of MYC-induced apoptosis in multiple solid tumours. Cell. Rep. 8(5), 1347–1353 (2014).
  MedlineGoogle Scholar
• 43. Liu Y, Zhu YH, Mao CQ et al. Triple-negative breast cancer therapy and CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles. J. Control. Rel. 192, 114–121 (2014).
  Medline CASGoogle Scholar
• 44. Yang A, Qin S, Schulte BA, Ethier SP, Kenneth DT, Wang GY. MYC inhibition depletes cancer stem-like cells in triple negative breast cancer. Cancer Res. 77(23), 6641–6650 (2017).
  Medline CASGoogle Scholar
• 45. Jones SK, Merkel OM. Tackling breast cancer chemoresistance with nano-formulated siRNA. Gene Ther. 23(12), 821–828 (2016).
  Medline CASGoogle Scholar
• 46. Mbatha LS, Maiyo FC, Singh M. Dendrimer functionalized folate-targeted gold nanoparticles for luciferase gene silencing in vitro: a proof of principle study. Acta Pharm. 69, 49–61 (2019).
  Medline CASGoogle Scholar
• 47. Deng Y, Wang CC, Choy KW et al. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Gene 538, 217–227 (2014).
  Medline CASGoogle Scholar
• 48. Thanki K, Zeng X, Justesen S et al. Engineering of small interfering RNA-loaded lipidoid-poly(DL-lactic-co-glycidic acid) hybrid nanoparticles for highly efficient and safe gene silencing. a quality by design-based approach. Eur. J. Pharma. Biopharm. 120, 22–33 (2017).
  Medline CASGoogle Scholar
• 49. Mbatha LS, Singh M. Starburst poly(amidoamine) dendrimer grafted gold nanoparticles as a scaffold for folic acid-targeted plasmid DNA delivery in vitro. J. Nanosci. Nanotechnol. 19(4), 1959–1970 (2019).
  Medline CASGoogle Scholar
• 50. Draz MS, Fang BA, Zhang P et al. Nanoparticle mediated systemic delivery of siRNA for treatment of cancers and viral infections. Theranostics 4(9), 872–892 (2014).
  Medline CASGoogle Scholar
• 51. Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev. 99(Pt A), 28–55 (2016).
  Medline CASGoogle Scholar
• 52. Shen Z, Fisher A, Liu NK, Li Y. PEGylated “stealth” nanoparticles and liposomes: engineering of biomaterials for drug delivery systems. In: Beyond Polyethylene Glycol. Woodhead Publishing Series in Biomaterials, 1–26 (2018).
  Google Scholar
• 53. Çağdaş M, Sezer AD, Bucak S. Liposomes as potential drug carrier systems for drug delivery. In: Application of Nanotechnology in Drug Delivery. InTechOpen Ltd, London, UK (2014).
  Google Scholar
• 54. Kesharwani P, Gajbhiye V, Jain NK. A review of nanocarriers for the delivery of small interfering RNA. Biomaterials 33, 7138–7150 (2012).
  Medline CASGoogle Scholar
• 55. Garćia-Pinel B, Porras-Alcalá C, Ortega-Rodŕiguez A et al. Lipid-based nanoparticles: applications and recent advances in cancer treatment. Nanomaterials 9(4), 638 (2019). •• Outlines lipid-based nanoparticles and their applications in cancer treatment.
  CASGoogle Scholar
• 56. Liu Y, Huang L. Designer lipids advance systemic siRNA delivery. Mol. Ther. 18, 669–670 (2010).
  Medline CASGoogle Scholar
• 57. Talluri SV, Kuppusamy G, Karri VVSR, Tummala S, Madhunapantula SV. Lipid-based nanocarriers for breast cancer treatment-comprehensive review. Drug Deliv. 23(4), 1291–1305 (2016).
  Medline CASGoogle Scholar
• 58. Hoekstra D, Rejman J, Wasungu L, Shi F, Zuhorn I. Gene delivery by cationic lipids: in and out of an endosome. Biochem. Soc. Trans. 35, 68–71 (2007).
  Medline CASGoogle Scholar
• 59. Nourbakhsh M, Jaafari MR, Lage H, Abnous K. Nanolipoparticles-mediated MDR1 siRNA delivery reduces doxorubicin resistance in breast cancer cells and silences MDR1 expression in xenograft model of human breast cancer. Iran. J. Basic Med. Sci. 18(4), 385–392 (2015).
  MedlineGoogle Scholar
• 60. Zhang Y, Li H, Sun J et al. DC-Chol/DOPE cationic liposomes: a comparative study of the influence factors on plasmid pDNA and siRNA gene delivery. Int. J. Pharm. 390, 198–207 (2010).
  Medline CASGoogle Scholar
• 61. Pirollo KF, Chang EH. Targeted delivery of small interfering RNA: approaching effective cancer therapies. Cancer Res. 68(5), 1247–1250 (2008).
  Medline CASGoogle Scholar
• 62. Brown S, Khan DR. The treatment of breast cancer using liposome technology. J. Drug Deliv. 2012, 212965 (2012).
  MedlineGoogle Scholar
• 63. Gao J, Zhang J, He J et al. Tumour-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes. Int. J. Pharm. 374(1–2), 145–152 (2009).
  Medline CASGoogle Scholar
• 64. Beltrán-Grazia E, López-Camacho A, Higura-Ciapara I, Velázquez-Fernandez J, Vallejo-Cardon A. Nanomedicine review: clinical developments in liposomal applcations. Cancer Nano. 10, 11 (2019).
  Google Scholar
• 65. Pandey H, Rani R, Agarwal V. Liposomes and their applications in cancer therapy. Braz. Arch. Biol.Technol. 59, e16150477 (2016).
  Google Scholar
• 66. Barenholz Y. Doxil (R) the first FDA-approved nano-drug lessons learned. J. Control. Rel. 160, 117–134 (2012).
  Medline CASGoogle Scholar
• 67. Batist G, Gelman KA, Chi LN et al. Safety, pharmacokinetics and efficacy of CPX-1 liposome injected in patients with solid tumours. Clin. Cancer Res. 15, 692–700 (2009).
  Medline CASGoogle Scholar
• 68. Boeckle S, von Gersdorff K, van der Piepen S, Culmsee C, Wagner E, Ogris M. Purification of polyethylenimine polyplexes highlights the role of free polycations in gene transfer. J. Gene Med. 6, 1102–1111 (2004).
  Medline CASGoogle Scholar
• 69. Xin Y, Huang M, Guo WW, Huang Q, Zhang L, Jiang G. Nano-based delivery of RNAi in cancer therapy. Mol. Cancer 16, 134 (2017).
  MedlineGoogle Scholar
• 70. Ragelle H, Riva R, Vandermeulen G et al. Chitosan nanoparticles for siRNA delivery: optimizing formulation to increase the stability and efficiency. J. Control. Rel. 176, 54–63 (2014).
  Medline CASGoogle Scholar
• 71. Mao S, Sun W, Kissel T. Chitosan-based formulations for delivery of DNA and siRNA. Adv. Drug Deliv. Rev. 62, 12–27 (2010).
  Medline CASGoogle Scholar
• 72. Grzelinski M, Urban-Klein B, Martens T et al. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Human Gene Ther. 17, 751–766 (2006).
  Medline CASGoogle Scholar
• 73. Garcia-Fuentes M, Alonso MJ. Chitosan based nanocarriers: where do we stand? J. Control. Rel. 161, 496–504 (2012).
  Medline CASGoogle Scholar
• 74. Yang S, Chen Y, Ahmadie R, Ho EA. Advancements in the field of intravaginal siRNA delivery. J. Control. Rel. 167, 29–39 (2013).
  Medline CASGoogle Scholar
• 75. Alinej V, Somi MH, Baradarem B et al. Co-delivery of IL178RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells. Biomed. Pharmacother. 83, 229–240 (2016).
  MedlineGoogle Scholar
• 76. Yu S, Chen Y, Li X, Gao Z, Liu G. Chitosan nanoparticle-delivered siRNA induces CXCR4 expression and sensitizes breast cancer cells to cisplatin. Biosci. Rep. 37(3), BSR20170122 (2017).
  Medline CASGoogle Scholar
• 77. Safari J, Zarnegar Z. Advanced drug delivery systems: nanotechnology of health design: A review. J. Saudi Chem. Soc. 18, 85–99 (2014).
  CASGoogle Scholar
• 78. Dzmitruk V, Apartsin E, Ihnatsyeu-Kachan A, Abashkin V, Shcharbin D, Bryszewska M. Dendrimers show promise for siRNA and microRNA therapeutics. Pharmaceutics 10, 126 (2018).
  CASGoogle Scholar
• 79. Abbasi E, Aval S, Akbarzadeh A et al. Dendrimers: synthesis, applications, and properties. Nanoscale Res. Lett. 9, 247 (2014).
  MedlineGoogle Scholar
• 80. Khan OF, Zaia EW, Yin H et al. Ionizable amphiphilic dendrimer-based nanomaterials with alkyl-chain-substituted amines for tunable siRNA delivery to the liver endothelium in vivo. Angew. Chem. Int. Ed. 53, 14397–14401 (2014).
  Medline CASGoogle Scholar
• 81. Liu X, Liu C, Zhou J et al. Promoting siRNA delivery via enhanced cellular uptake using arginine-decorated amphiphilic dendrimer. Nanoscale 7, 3867–3875 (2015).
  Medline CASGoogle Scholar
• 82. Deshahri A, Sadeghpour H. Surface decorations of poly(amido amine) dendrimer by various pendant moieties for improve delivery of nucleic acid materials. Colloids Surf. B 132, 85–102 (2015).
  MedlineGoogle Scholar
• 83. Finlay J, Roberts CM, Lowe G, Loeza J, Rossi JJ, Glackin CA. RNA based TWIST1 inhibition via dendrimer complex to reduce breast cancer cell metastasis. BioMed Res. Int. 2015, 382745 (2015).
  MedlineGoogle Scholar
• 84. Li J, Liu J, Guo N, Zhang Z. Reversal of multidrug resistance in breast cancer MCF-7/ADR cells by h-R3-siMDR1-PAMAM complexes. Int. J. Pharm. 511(1), 436–445 (2016).
  Medline CASGoogle Scholar
• 85. Ngamcherdtrakul W, Castro DJ, Gu S et al. Current development of targeted oligonucleotide-based cancer therapies: perspective on HER2-positive breast cancer treatment. Cancer Treat. Rev. 45, 19–29 (2016).
  Medline CASGoogle Scholar
• 86. Herizchi R, Abbasi E, Milani M, Akbarzadeh A. Current methods for synthesis of gold nanoparticles. Artif. Cells Nanomed. Biotechnol. 44(2), 596–602 (2016).
  Medline CASGoogle Scholar
• 87. Moon HJ, Ku M, Lee H, Yoon N, Yang J, Bong KW. Implantable photothermal agents based on gold nanorods-encapsulated microcube. Sci. Rep. 8(1), 13683 (2018).
  MedlineGoogle Scholar
• 88. Shahbazi R, Asik E, Kahraman N, Turk M, Ozpolat B, Ulubayram K. Modified gold-based siRNA nanotherapeutics for targeted therapy of triple-negative breast cancer. Nanomedicine 12(16), 1961–1973 (2017).
  CASGoogle Scholar
• 89. Daniels AN, Singh M. Sterically stabilized siRNA:gold nanocomplexes enhance c-MYC silencing in a breast cancer cell model. Nanomedicine 14(11), 1387–1401 (2019).
  CASGoogle Scholar
• 90. Ahwazi RP, Kiani M, Dinarvand M et al. Immobilization of HIV-1 TAT peptide on gold nanoparticles: a feasible approach for siRNA delivery. J. Cell. Phys. 235(3), 2049–2059 (2020).
  Medline CASGoogle Scholar
• 91. Shen J, Kim H-C, Mu C et al. Multifunctional gold nanorods for siRNA gene silencing and photothermal therapy. Adv. Healthcare Mater. 3(10), 1629–1637 (2014a).
  Medline CASGoogle Scholar
• 92. Yang Z, Liu T, Xie Y et al. Chitosan layered gold nanorods as synergistic therapeutics for photothermal ablation and gene silencing in triple-negative breast cancer. Acta Biomater. 25, 194–204 (2015).
  Medline CASGoogle Scholar
• 93. Wang S, Tian Y, Tian W et al. Selectively sensitizing malignant cells to photothermal therapy using a CD44-targeting heat shock protein 72 depletion nanosystem. ACS Nano. 10(9), 8578–8590 (2016).
  Medline CASGoogle Scholar
• 94. Moodley T, Singh M. Polymeric mesoporous silica nanoparticles for enhanced delivery of 5-fluorouracil in vitro. Pharmaceutics 11(6), 288 (2019).
  CASGoogle Scholar
• 95. Xu C, Lei C, Yu C. Mesoporous silica nanoparticles for protein protection and delivery. Front. Chem. 7, 290 (2019).
  Medline CASGoogle Scholar
• 96. Shen J, Kim H-C, Su H et al. Cyclodextrin and polyethylenimine functionalized mesoporous silica nanoparticles for delivery of siRNA cancer therapeutics. Theranostics 4(5), 487–497 (2014b).
  Medline CASGoogle Scholar
• 97. Na H-K, Kim M-H, Park K et al. Efficient functional delivery of siRNA using mesoporous silica nanoparticles with ultralarge pores. Small 8(11), 1752–1761 (2012).
  Medline CASGoogle Scholar
• 98. Meng H, Mai WX, Zhang H et al. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano 7(2), 994–1005 (2013).
  Medline CASGoogle Scholar
• 99. Matea CT, Mocan T, Tabaran F et al. Quantum dots in imaging, drug delivery and sensor applications. Int. J. Nanom. 12, 5421–5431 (2017).
  CASGoogle Scholar
• 100. Zhao J, Qiu X, Wang Z, Pan J, Chen J, Han J. Application of quantum dots as vectors in targeted survivin gene siRNA delivery. OncoTargets Ther. 6, 303–309 (2013).
  Medline CASGoogle Scholar
• 101. Yoo D, Park Y, Cheon B, Park M-H. Carbon dots as an effective fluorescent sensing platform for metal ion detection. Nanoscale Res. Lett. 14(1), 272 (2019).
  MedlineGoogle Scholar
• 102. Fernández-Delgado N, Herrera M, Tavabi AH et al. Structural and chemical characterization of CdSe-ZnS core–shell quantum dots. Appl. Surf. Sci. 457, 93–97 (2018).
  CASGoogle Scholar
• 103. Kim MW, Jeong HY, Kang SJ et al. Anti-EGF receptor aptamer-guided co-delivery of anti-cancer siRNAs and quantum dots for theranostics of triple-negative breast cancer. Theranostics 9(3), 837–852 (2019).
  Medline CASGoogle Scholar
• 104. Majidi S, Zeinali Sehrig F, Samiei M et al. Magnetic nanoparticles: applications in gene delivery and gene therapy. Artif. Cells Nanomed. Biotechnol. 44(4), 1186–1193 (2015).
  MedlineGoogle Scholar
• 105. Ali A, Zafar H, Zia M et al. Synthesis, characterization, applications, and challenges of iron oxide nanoparticles. Nanotechnol. Sci. Appl. 9, 49–67 (2016).
  Medline CASGoogle Scholar
• 106. Ben Djemaa S, David S, Hervé-Aubert K et al. Formulation and in vitro evaluation of a siRNA delivery nanosystem decorated with gH625 peptide for triple negative breast cancer theranosis. Eur. J. Pharm. Biopharm. 131, 99–108 (2018).
  MedlineGoogle Scholar
• 107. Ansari MO, Ahmad MF, Shadab GGHA, Siddique HR. Superparamagnetic iron oxide nanoparticles based cancer theranostics: a double edge sword to fight against cancer. J. Drug Deliv. Sci. Technol. 45, 177–183 (2018).
  CASGoogle Scholar
• 108. Bruniaux J, Allard-Vannier E, Aubrey N et al. Magnetic nanocarriers for the specific delivery of siRNA: contribution of breast cancer cells active targeting for down-regulation efficiency. Int. J. Pharm. 569, 118572 (2019).
  Medline CASGoogle Scholar
• 109. Dalmina M, Pittella F, Sierra JA et al. Magnetically responsive hybrid nanoparticles for in vitro siRNA delivery to breast cancer cells. Mater. Sci. Eng. C 99, 1182–1190 (2019).
  Medline CASGoogle Scholar
• 110. Guruprasath P, Kim J, Gunassekaran GR et al. Interleukin-4 receptor-targeted delivery of Bcl-xL siRNA sensitizes tumors to chemotherapy and inhibits tumor growth. Biomaterials 142, 101–111 (2017).
  Medline CASGoogle Scholar
• 111. Sanginario A, Miccoli B, Demarchi D. Carbon nanotubes as an effective opportunity for cancer diagnosis and treatment. Biosensors 7(1), 9 (2017).
  Google Scholar
• 112. Wong BS, Yoong SL, Jagusiak A et al. Carbon nanotubes for delivery of small molecule drugs. Adv. Drug Deliv. Rev. 65(15), 1964–2015 (2013).
  Medline CASGoogle Scholar
• 113. Mohammadi M, Salmasi Z, Hashemi M, Mosaffa F, Abnous K, Ramezani M. Single-walled carbon nanotubes functionalized with aptamer and piperazine–polyethylenimine derivative for targeted siRNA delivery into breast cancer cells. Int. J. Pharm. 485(1–2), 50–60 (2015).
  Medline CASGoogle Scholar
• 114. Alhaji SY, Chowdhury EH, Rosli R, Hassan F, Abdullah S. Gene delivery potential of biofunctional carbonate apatite nanoparticles in lungs. BioMed Res. Int. 2014, 646787 (2014).
  MedlineGoogle Scholar
• 115. Chowdhury EH, Akaike T. High performance DNA nano-carriers of carbonate apatite: multiple factors in regulation of particle synthesis and transfection efficiency. Int. J. Nanomed. 2(1), 101–106 (2007).
  Medline CASGoogle Scholar
• 116. Hossain SM, Shetty J, Tha KK, Chowdhury EH. α-Ketoglutaric acid-modified carbonate apatite enhances cellular uptake and cytotoxicity of a Raf-kinase inhibitor in breast cancer cells through inhibition of MAPK and PI-3 kinase pathways. Biomedicines 7(1), 4 (2019).
  CASGoogle Scholar
• 117. Fatemian T, Moghimi HR, Chowdhury EH. Intracellular delivery of siRNAs targeting AKT and ERBB2 genes enhances chemosensitization of breast cancer cells in a culture and animal model. Pharmaceutics 11(9), 458 (2019).
  CASGoogle Scholar
• 118. Tiash S, Chua MJ, Chowdhury EH. Knockdown of ROS1 gene sensitizes breast tumor growth to doxorubicin in a syngeneic mouse model. Int. J. Oncol. 48(6), 2359–2366 (2016).
  Medline CASGoogle Scholar
• 119. Uddin M, Balaravi Pillai B, Tha K, Ashaie M, Karim M, Chowdhury E. Carbonate apatite nanoparticles-facilitated intracellular delivery of siRNA(s) targeting calcium ion channels efficiently kills breast cancer cells. Toxics 6(3), 34 (2018).
  CASGoogle Scholar